A grand opening ceremony of “Max-Well” Scientific Oncological and Cardiological Production Center, a unique manufacturing complex producing immunobiological and chemico-pharmaceutical products, was held on March 26th in the town of Borispol, Kiev region.

The production facility is unique, because it was initially designed and built according to GMP standards (Good Manufacturing Practice), the world-wide regulations for production of drug products. Also, both chemico-pharmaceutical and immunobiological drug products will be manufactured at the production facility, which is innovative not only for Ukraine, but for the CIS countries practice as well.

The grand opening of pharmaceutical production plant was launched by the Ambassador of the United States to Ukraine William Taylor, chairman of the board of directors of BTA Bank Muhtar Ablyazov,  and president of Max-Well Dr. Ken Alibek.

"The production facilities of the enterprise, being analogue-free in Ukraine, will permit to manufacture over 200 million capsules, about 150 million pills, 60 million vials, 30 million pre-filled syringes and 30 million suppositories per year. Just at this enterprise the drug products for treatment of oncological, cardiological and severe viral diseases will be manufactured", - Mr. Vladimir Bugaychuk, General Director of SOCPC "Max-Well" stated.

In addition, "Max-Well" is planning to concentrate on manufacturing generics, the drug products similar to medications, which are developed and produced by the famous leading producers of pharmaceuticals and proved their effectiveness.

"This approach will allow to substantially reduce the cost of the manufactured drug products, it means that the Ukrainian citizens will receive effective drug products at a lower cost to treat the most widespread diseases today." - Mr. V. Bugaychuk emphasized.

The Scientific Oncological and Cardiological Production Center “Max-Well” is the first in Ukraine and the largest in the former Soviet Union profiled complex, which combines the Polyclinic center for diagnostics and treatment of cardiological and oncological diseases, manufacturing of drug products and the research-and-development center. At present the SOCPC “Max-Well" is the biggest international investment in the Ukrainian pharmaceutical branch. The total investment volume in this project has already made up over US $90 million dollars, and in the nearest future the investment amount will increase up to US $130 million dollars. The investment fund of the project on production facility construction in Ukraine was formed by Mr. Mukhtar Ablyazov, the Chairman of the Board of Directors at JSC "BTA Bank", a highly regarded and accomplished international businessman.